JXR (01951) saw an intraday surge of more than 7%. At the time of writing, the stock was up 5.28%, trading at HK$2.59 with a turnover of HK$165 million. According to a January 6th announcement from JXR, as the year concluded, the company's operational data for the fourth quarter continued the improving trend seen in the first three quarters, demonstrating resilient and consistently positive business performance. By the end of 2025, the year-on-year decline in the cumulative number of IVF egg retrieval cycles had narrowed to 1.4%, improving from the 5.2% drop recorded over the first three quarters. Haitong International previously noted that as a leading domestic player in assisted reproduction, the company stands to benefit from ongoing enhancements to fertility policies in both China and the US, with potential for marginal earnings improvement in 2026, building off a low comparative base.